ClinicalTrials.gg
CompletedNCT00205803Updated Aug 15, 2012Results posted

Study Evaluating Pneumococcal Vaccine in Healthy Infants

A Phase 1/2 interventional study of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) and 7-Valent Pneumococcal Conjugate Vaccine (7vPnC) in Healthy Subjects and Pneumococcal Infections, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 1 site in United States. Open to participants aged 42 Days to 98 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-08-15.

Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 1/2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
249
Allocation
Randomized
Ages
42 Days to 98 Days
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections — none open to participants now, 1 under way, none of them phase 3. 13-valent pneumococcal vaccine · Pneumococcal Infections.

Enrollment
27th of 44
249 · median 328
Started
2004
the only one that year
Phase 1/2
Only one
of the 44
Registered
1st of 44
by date
Lead sponsor
4 of 44
Wyeth is now a wholly owned subsidiary of Pfizer

Among the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections, this one is the 27th largest by enrollment, is the only one that started in 2004, is the only one in phase 1/2, and was the 1st registered.

Pneumococcal Infections

299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

None of the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections is open now. The open studies under Pneumococcal Infections, anywhere →

About 13-valent pneumococcal vaccine

13-valent pneumococcal vaccine: first FDA approval 2010 (Prevnar 13). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 42 Days to 98 Days · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections as a file.
02

Study summary

The purpose of this study is to evaluate the safety and immunogenicity of the 13-valent pneumococcal conjugate vaccine (13vPnC) in healthy infants. This is the first study with this vaccine in infants.

03

Conditions studied

  • Healthy Subjects
  • Pneumococcal Infections

Keywords

  • Infant Vaccine
04

Who can participate

Ages eligible
42 Days to 98 Days
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 6 weeks to 14 weeks (42-98 days of age) at time of enrollment,
  2. In good health as determined by medical history, physical examination and judgment of the investigator,
  3. Subject must have been born ≥36 weeks of gestational age,
  4. Subject must be available for entire study period and whose parent/legal guardian can be reached by telephone,
  5. Parent/legal guardian must be able to understand and sign an form prior to participation and complete a parent worksheet during study participation.

Exclusion criteria

Exclusion Criteria:

  1. Previous vaccination with licensed or pneumococcal vaccine,
  2. Previous vaccination with Hib conjugate, DTaP or IPV vaccines,
  3. to immunization with HepB, Hib conjugate, DTaP or IPV vaccines,
  4. Significant neurological disorder or history of seizure including febrile seizure, or significant stable or evolving disorders such as cerebral palsy, encephalopathy, hydrocephalus or other significant disorders. Does not include resolving syndromes due to birth trauma such as Erb palsy,
  5. Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection,
  6. History of culture-proven invasive disease caused by S. pneumoniae,
  7. Previous anaphylactic reaction to any vaccine or vaccine components,
  8. Major known congenital malformation or serious chronic disorders,
  9. Participation in another investigational study (however, observation-only trials are permitted),
  10. Known or suspected immune deficiency/suppression,
  11. Receipt of blood products or gamma globulin (including immunoglobulin and monoclonal antibody; eg, Synagis®).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
249 participants (actual)

Study arms

  • Experimental
    13vPnC

    Biological: 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)

  • Active comparator
    7vPnC

    Biological: 7-Valent Pneumococcal Conjugate Vaccine (7vPnC)

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Reporting Pre-Specified Local Reactions

    Local reaction events were collected using a paper worksheet. Tenderness was scaled as Any (tenderness present); Significant (Sig.) (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (Mod.)(2.5 to 7.0 cm); Severe (Sev.)(\> 7.0 cm). Participants may be represented in more than 1 category.

    Time frame: Within 15 days after each dose

  2. Percentage of Participants Reporting Pre-Specified Systemic Events

    Systemic events (fever \[Fv\] ≥ 38 degrees Celsius \[C\] but ≤ 39 C, fever \>39 C but ≤ 40 C, fever \> 40 C, decreased (decr.) appetite, irritability, increased sleep, decreased sleep, use of medication (Med.)to prevent symptoms (sx), and use of medication to treat symptoms) were reported using a paper worksheet. Participants may be represented in more than 1 category.

    Time frame: Within 15 days after each dose

  3. Percentage of Participants Achieving Antibody Level ≥0.35μg/mL in 13vPnC Group Relative to 7vPnC Group After the 3-Dose Infant Series

    Percentage of participants achieving World Health Organization (WHO) predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.

    Time frame: one month after 3-dose infant series (at 7 months of age)

Secondary outcomes

  1. Percentage of Participants Achieving Antibody Level ≥0.35μg/mL in 13vPnC Group Relative to 7vPnC Group After the Toddler Dose

    Percentages of participants achieving WHO predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.

    Time frame: One month after the toddler dose (at 13 to 16 months of age)

  2. Geometric Mean Antibody Concentration in 13vPnC Group Relative to 7vPnC Group After the 3-Dose Infant Series

    Antibody geometric mean concentration (GMC) as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC ratios (13vPnC/7vPnC) and corresponding 2-sided 95% CI were evaluated.

    Time frame: One month after 3-dose infant series (at 7 months of age)

  3. Geometric Mean Concentration in 13vPnC Group Relative to 7vPnC Group Before and After the Toddler Dose

    Antibody geometric mean concentration (GMC) as measured by ELISA with their corresponding 95% CI immediately before and after the toddler dose for 7 common pneumococcal serotypes (Serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

    Time frame: Immediately before (12 to 15 months of age) and one month after the toddler dose (13 to 16 months of age)

  4. Percentage of Participants Achieving Predefined Antibody Levels for Haemophilus Influenzae Type b, Diphtheria Toxoid, Polio, Pertussis, Tetanus, and Hepatitis B in 13vPnC Group Relative to 7vPnC Group After the Infant Series

    Percentage of participants achieving predefined antibody threshold levels for Haemophilus Influenzae Type b (Hib) polyribosylribitol phosphate (PRP), Diphtheria Toxoid, Polio (Types 1, 2, and 3), Pertussis (filamentous hemagglutinin \[FHA\], Pertussis Toxoid, and Pertactin), Tetanus, and Hepatitis B with the corresponding 95% CI for each concomitant antigen are presented.

    Time frame: One month after the infant series (7 months of age)

  5. Geometric Mean Antibody Concentration of Haemophilus Influenzae Type b in 13vPnC Group Relative to 7vPnC Group After the Infant Series

    Time frame: one month after the infant series (7 months of age)

  6. Geometric Mean Antibody Concentration of Hepatitis B in 13vPnC Group Relative to 7vPnC Group After the Infant Series

    GMCs of anti-hepatitis B surface antigen (HBsAg) using a Food and Drug Administration (FDA) approved in vitro diagnostic kit are presented.

    Time frame: one month after the infant series (7 months of age)

  7. Geometric Mean Antibody Concentration Diphtheria Toxoid and Anti-Tetanus Toxoid in 13vPnC Group Relative to 7vPnC Group After the Infant Series

    Time frame: one month after the infant series (7 months of age)

  8. Geometric Mean Antibody Concentration of Polio in 13vPnC Group Relative to 7vPnC Group After the Infant Series

    Time frame: one month after the infant series (7 months of age)

  9. Geometric Mean Antibody Concentration of Pertussis Antigens in 13vPnC Group Relative to 7vPnC Group After the Infant Series

    Time frame: one month after the infant series (7 months of age)

  10. Percentage of Participants Achieving Antibody Titer (OPA) ≥1:8 in 13vPnC Group Relative to 7vPnC Group After the 3-Dose Infant Series

    Percentage of participants achieving functional antibody titer ≥1:8 as measured by opsonophagocytic activity assay (OPA) along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

    Time frame: one month after the infant series (7 months of age)

  11. Percentage of Participants Achieving Antibody Titer (OPA) ≥1:8 in 13vPnC Group Relative to 7vPnC Group After the Toddler Dose

    Percentage of participants achieving functional antibody titer ≥1:8 as measured by opsonophagocytic activity assay (OPA) along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) were assessed. Results are reported for the serotypes with a determinate antibody titer.

    Time frame: One month after the toddler dose (13 to 16 months of age)

  12. Geometric Mean Antibody Titer (OPA) in 13vPnC Group Relative to 7vPnC Group After the Toddler Dose

    Antibody functionality/geometric mean titer (GMT) as measured by opsonophagocytic activity assay (OPA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) were assessed. Results are reported for the serotypes with a determinate antibody titer.

    Time frame: One month after the Toddler Dose (13 to 16 months of age)

07

Results

Posted Aug 15, 2012

Participant flow

Participants were recruited in the United States from September 2004 to September 2005.

Infant Series
Participant flow — Infant Series
Milestone13vPnC7vPnC
Started122127
Vaccinated dose 1121126
Vaccinated dose 2115122
Vaccinated dose 3110118
Completed104116
Not completed1811
Withdrew: Lost to follow-up104
Withdrew: Withdrawal by subject25
Withdrew: Physician decision31
Withdrew: Protocol violation10
Withdrew: Lost kaiser coverage01
Withdrew: Non-compliant10
Withdrew: Sponsor request10
After Infant Series
Participant flow — After Infant Series
Milestone13vPnC7vPnC
Started104116
Completed86103
Not completed1813
Withdrew: Adverse event11
Withdrew: Protocol violation11
Withdrew: Lost to follow-up21
Withdrew: Physician decision32
Withdrew: Withdrawal by subject14
Withdrew: Other104
Toddler Dose
Participant flow — Toddler Dose
Milestone13vPnC7vPnC
Started86103
Completed84100
Not completed23
Withdrew: Lost to follow-up23

Outcome measures

PrimaryPercentage of Participants Reporting Pre-Specified Local Reactions

Local reaction events were collected using a paper worksheet. Tenderness was scaled as Any (tenderness present); Significant (Sig.) (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (Mod.)(2.5 to 7.0 cm); Severe (Sev.)(\> 7.0 cm). Participants may be represented in more than 1 category.

Time frame:
Within 15 days after each dose
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-Specified Local Reactions
percentage of participants13vPnC Dose 17vPnc Dose 113vPnC Dose 27vPnC Dose 213vPnC Dose 37vPnC Dose 313vPnC Toddler Dose7vPnC Toddler Dose
Tenderness-Any (n=119,124,110,118,107,117,85,101)34.543.528.236.424.325.622.429.7
Tenderness-Sig. (n=119,124,110,118,107,117,85,101)8.45.61.88.54.76.02.44.0
Induration-Any (n=119,124,110,118,107,117,85,100)21.819.416.419.516.818.818.817.0
Induration-Mild (n=119,123,110,117,107,116,85,100)20.217.916.417.116.817.218.817.0
Induration-Mod. (n=119,123,110,117,107,116,85,100)3.42.43.63.40.04.32.43.0
Induration-Sev. (n=119,123,110,117,107,116,85,100)0.00.00.00.00.00.00.00.0
Erythema-Any (n=119,124,111,118,107,117, 85,100)21.019.416.217.817.819.724.719.0
Erythema-Mild (n=119,124,110,117,106,116,85,99)20.219.413.617.116.018.124.716.2
Erythema-Mod. (n=119,124,108,117,106,116,85,99)2.50.02.80.00.92.63.55.1
Erythema-Severe (n=119,124,108,117,106,116,85,99)0.00.00.00.00.00.00.00.0
PrimaryPercentage of Participants Reporting Pre-Specified Systemic Events

Systemic events (fever \[Fv\] ≥ 38 degrees Celsius \[C\] but ≤ 39 C, fever \>39 C but ≤ 40 C, fever \> 40 C, decreased (decr.) appetite, irritability, increased sleep, decreased sleep, use of medication (Med.)to prevent symptoms (sx), and use of medication to treat symptoms) were reported using a paper worksheet. Participants may be represented in more than 1 category.

Time frame:
Within 15 days after each dose
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-Specified Systemic Events
percentage of participants13vPnC Dose 17vPnc Dose 113vPnC Dose 27vPnC Dose 213vPnC Dose 37vPnC Dose 313vPnC Toddler Dose7vPnC Toddler Dose
Fv ≥38°C but≤39°C(n=114,121,102,114,100,113,78,94)16.716.521.624.620.020.414.112.8
Fv >39°C but≤40°C(n=113,121,102,113,101,113,77,94)2.70.83.93.52.00.92.60.0
Fv >40°C (n=113,121,102,113,100,113,76,94)0.00.00.00.00.00.00.00.0
Decr. Appetite (n=118,124,110,118,107,117,85,101)30.531.522.722.927.130.822.421.8
Decr. Sleep (n=118,124,110,118,107,117,84,101)18.617.724.519.521.518.813.114.9
Increased Sleep (n=119,124,111,118,107,117,86,101)56.354.042.346.634.641.027.943.6
Irritability (n=118,124,110,118,107,117,85,101)66.971.062.756.851.453.838.847.5
Med.-Prevent Sx (n=95,101,86,96,83,93,85,102)29.533.734.932.336.143.017.635.3
Med.-Treat Symptoms (n=94,101,86,96,84,94,85,101)44.734.748.850.042.947.929.427.7
PrimaryPercentage of Participants Achieving Antibody Level ≥0.35μg/mL in 13vPnC Group Relative to 7vPnC Group After the 3-Dose Infant Series

Percentage of participants achieving World Health Organization (WHO) predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.

Time frame:
one month after 3-dose infant series (at 7 months of age)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Antibody Level ≥0.35μg/mL in 13vPnC Group Relative to 7vPnC Group After the 3-Dose Infant Series
percentage of participants13vPnC7vPnC
Common Serotypes - Serotype 4 (n=94,107)96.81 (90.96 to 99.34)99.07 (94.90 to 99.98)
Common Serotypes - Serotype 6B (n=94,107)88.30 (80.03 to 94.01)88.79 (81.23 to 94.07)
Common Serotypes - Serotype 9V (n=94,108)96.81 (90.96 to 99.34)99.07 (94.95 to 99.98)
Common Serotypes - Serotype 14 (n=94,107)97.87 (92.52 to 99.74)97.20 (92.02 to 99.42)
Common Serotypes - Serotype 18C (n=94,106)96.81 (90.96 to 99.34)99.06 (94.86 to 99.98)
Common Serotypes - Serotype 19F (n=94,106)97.87 (92.52 to 99.74)97.17 (91.95 to 99.41)
Common Serotypes - Serotype 23F (n=94,108)94.68 (88.02 to 98.25)95.37 (89.53 to 98.48)
Additional Serotypes - Serotype 1 (n=94,108)97.87 (92.52 to 99.74)25.00 (17.17 to 34.25)
Additional Serotypes - Serotype 3 (n=94,107)98.94 (94.21 to 99.97)14.02 (8.06 to 22.07)
Additional Serotypes - Serotype 5 (n=93,107)100.00 (96.11 to 100.00)42.06 (32.58 to 51.99)
Additional Serotypes - Serotype 6A (n=93,106)96.77 (90.86 to 99.33)33.96 (25.04 to 43.80)
Additional Serotypes - Serotype 7F (n=94,105)98.94 (94.21 to 99.97)6.67 (2.72 to 13.25)
Additional Serotypes - Serotype 19A (n=94,107)100.00 (96.15 to 100.00)94.39 (88.19 to 97.91)
Statistical analysis
  • 13vPnC vs 7vPnC · Difference: -2.26 · 95% CI -8.08 to 2.33
  • 13vPnC vs 7vPnC · Difference: -0.49 · 95% CI -9.93 to 8.65
  • 13vPnC vs 7vPnC · Difference: -2.27 · 95% CI -8.07 to 2.26
  • 13vPnC vs 7vPnC · Difference: 0.68 · 95% CI -4.96 to 6.16
  • 13vPnC vs 7vPnC · Difference: -2.25 · 95% CI -8.18 to 2.36
  • 13vPnC vs 7vPnC · Difference: 0.70 · 95% CI -4.84 to 6.32
  • 13vPnC vs 7vPnC · Difference: -0.69 · 95% CI -7.75 to 5.86
  • 13vPnC vs 7vPnC · Difference: 72.87 · 95% CI 63.32 to 81.07
  • 13vPnC vs 7vPnC · Difference: 84.92 · 95% CI 76.73 to 91.05
  • 13vPnC vs 7vPnC · Difference: 57.94 · 95% CI 48.01 to 67.42
  • 13vPnC vs 7vPnC · Difference: 62.81 · 95% CI 52.33 to 72.20
  • 13vPnC vs 7vPnC · Difference: 92.27 · 95% CI 85.26 to 96.54
  • 13vPnC vs 7vPnC · Difference: 5.61 · 95% CI 1.23 to 11.86
SecondaryPercentage of Participants Achieving Antibody Level ≥0.35μg/mL in 13vPnC Group Relative to 7vPnC Group After the Toddler Dose

Percentages of participants achieving WHO predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.

Time frame:
One month after the toddler dose (at 13 to 16 months of age)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Antibody Level ≥0.35μg/mL in 13vPnC Group Relative to 7vPnC Group After the Toddler Dose
percentage of participants13vPnC7vPnC
Common Serotypes - Serotype 4 (n=78,94)97.4 (91.0 to 99.7)98.9 (94.2 to 100.0)
Common Serotypes - Serotype 6B (n=78,93)100.0 (95.4 to 100.0)100.0 (96.1 to 100.0)
Common Serotypes - Serotype 9V (n=78,94)98.7 (93.1 to 100.0)100.0 (96.2 to 100.0)
Common Serotypes - Serotype 14 (n=78,93)100.0 (95.4 to 100.0)100.0 (96.1 to 100.0)
Common Serotypes - Serotype 18C (n=78,94)100.0 (95.4 to 100.0)100.0 (96.2 to 100.0)
Common Serotypes - Serotype 19F (n=78,93)100.0 (95.4 to 100.0)100.0 (96.1 to 100.0)
Common Serotypes - Serotype 23F (n=78,93)100.0 (95.4 to 100.0)97.8 (92.4 to 99.7)
Additional Serotypes - Serotype 1 (n=78,91)100.00 (95.4 to 100.00)2.2 (0.3 to 7.7)
Additional Serotypes - Serotype 3 (n=78,92)92.3 (84.0 to 97.1)8.7 (3.8 to 16.4)
Additional Serotypes - Serotype 5 (n=78,78)100.0 (95.4 to 100.0)70.5 (59.1 to 80.3)
Additional Serotypes - Serotype 6A (n=78,92)100.0 (95.4 to 100.0)88.0 (79.6 to 93.9)
Additional Serotypes - Serotype 7F (n=78,85)100.0 (95.4 to 100.0)5.9 (1.9 to 13.2)
Additional Serotypes - Serotype 19A (n=78,93)100.0 (95.4 to 100.0)100.0 (96.1 to 100.0)
Statistical analysis
  • 13vPnC vs 7vPnC · Difference: -1.5 · 95% CI -7.9 to 3.6
  • 13vPnC vs 7vPnC · Difference: 0.0 · 95% CI -4.6 to 4.0
  • 13vPnC vs 7vPnC · Difference: -1.3 · 95% CI -6.9 to 2.8
  • 13vPnC vs 7vPnC · Difference: 0.0 · 95% CI -4.6 to 4.0
  • 13vPnC vs 7vPnC · Difference: 0.0 · 95% CI -4.7 to 3.9
  • 13vPnC vs 7vPnC · Difference: 0.0 · 95% CI -4.6 to 4.0
  • 13vPnC vs 7vPnC · Difference: 2.2 · 95% CI -2.6 to 7.7
  • 13vPnC vs 7vPnC · Difference: 97.8 · 95% CI 92.3 to 99.7
  • 13vPnC vs 7vPnC · Difference: 83.6 · 95% CI 73.2 to 90.8
  • 13vPnC vs 7vPnC · Difference: 29.5 · 95% CI 19.7 to 40.9
  • 13vPnC vs 7vPnC · Difference: 12.0 · 95% CI 5.9 to 20.4
  • 13vPnC vs 7vPnC · Difference: 94.1 · 95% CI 86.8 to 98.1
  • 13vPnC vs 7vPnC · Difference: 0.0 · 95% CI -4.6 to 4.0
SecondaryGeometric Mean Antibody Concentration in 13vPnC Group Relative to 7vPnC Group After the 3-Dose Infant Series

Antibody geometric mean concentration (GMC) as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC ratios (13vPnC/7vPnC) and corresponding 2-sided 95% CI were evaluated.

Time frame:
One month after 3-dose infant series (at 7 months of age)
Reported as:
Geometric mean · μg/mL
Geometric Mean Antibody Concentration in 13vPnC Group Relative to 7vPnC Group After the 3-Dose Infant Series
μg/mL13vPnC7vPnC
Common Serotypes - Serotype 4 (n=94,107)1.81 (1.54 to 2.13)2.40 (2.01 to 2.87)
Common Serotypes - Serotype 6B (n=94,107)2.74 (2.02 to 3.71)2.86 (2.09 to 3.91)
Common Serotypes - Serotype 9V (n=94,108)1.52 (1.29 to 1.78)1.78 (1.55 to 2.05)
Common Serotypes - Serotype 14 (n=94,107)4.24 (3.44 to 5.23)5.19 (4.13 to 6.52)
Common Serotypes - Serotype 18C (n=94,106)1.53 (1.30 to 1.80)2.46 (2.08 to 2.91)
Common Serotypes - Serotype 19F (n=94,106)2.21 (1.87 to 2.61)2.58 (2.17 to 3.08)
Common Serotypes - Serotype 23F (n=94,108)1.39 (1.15 to 1.67)1.81 (1.51 to 2.19)
Additional Serotypes - Serotype 1 (n=94,108)2.57 (2.14 to 3.08)0.06 (0.05 to 0.09)
Additional Serotypes - Serotype 3 (n=94,107)1.40 (1.20 to 1.62)0.09 (0.07 to 0.11)
Additional Serotypes - Serotype 5 (n=93,107)2.41 (2.07 to 2.80)0.28 (0.22 to 0.34)
Additional Serotypes - Serotype 6A (n=93,106)2.36 (1.89 to 2.94)0.25 (0.20 to 0.30)
Additional Serotypes - Serotype 7F (n=94,105)1.85 (1.62 to 2.11)0.07 (0.06 to 0.08)
Additional Serotypes - Serotype 19A (n=94,107)1.93 (1.64 to 2.27)1.12 (0.96 to 1.32)
Statistical analysis
  • 13vPnC vs 7vPnC · Ratio: 0.76 · 95% CI 0.59 to 0.96
  • 13vPnC vs 7vPnC · Ratio: 0.96 · 95% CI 0.62 to 1.48
  • 13vPnC vs 7vPnC · Difference: 0.85 · 95% CI 0.69 to 1.05
  • 13vPnC vs 7vPnC · Ratio: 0.82 · 95% CI 0.60 to 1.11
  • 13vPnC vs 7vPnC · Ratio: 0.62 · 95% CI 0.49 to 0.79
  • 13vPnC vs 7vPnC · Ratio: 0.86 · 95% CI 0.67 to 1.09
  • 13vPnC vs 7vPnC · Ratio: 0.77 · 95% CI 0.59 to 1.00
  • 13vPnC vs 7vPnC · Ratio: 39.78 · 95% CI 27.47 to 57.63
  • 13vPnC vs 7vPnC · Ratio: 15.56 · 95% CI 11.63 to 20.81
  • 13vPnC vs 7vPnC · Ratio: 8.67 · 95% CI 6.65 to 11.29
  • 13vPnC vs 7vPnC · Ratio: 9.60 · 95% CI 7.07 to 13.04
  • 13vPnC vs 7vPnC · Ratio: 26.78 · 95% CI 20.97 to 34.22
  • 13vPnC vs 7vPnC · Ratio: 1.71 · 95% CI 1.36 to 2.16
SecondaryGeometric Mean Concentration in 13vPnC Group Relative to 7vPnC Group Before and After the Toddler Dose

Antibody geometric mean concentration (GMC) as measured by ELISA with their corresponding 95% CI immediately before and after the toddler dose for 7 common pneumococcal serotypes (Serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

Time frame:
Immediately before (12 to 15 months of age) and one month after the toddler dose (13 to 16 months of age)
Reported as:
Geometric mean · μg/mL
Geometric Mean Concentration in 13vPnC Group Relative to 7vPnC Group Before and After the Toddler Dose
μg/mL13vPnC Before Toddler Dose7vPnC Before Toddler Dose13vPnC After Toddler Dose7vPnC After Toddler Dose
Common Serotypes-Serotype 4 (n=83,100,78,94)0.33 (0.28 to 0.40)0.48 (0.41 to 0.56)2.86 (2.31 to 3.55)4.09 (3.34 to 5.00)
Common Serotypes-Serotype 6B (n=82,98,78,93)0.84 (0.69 to 1.03)0.95 (0.77 to 1.18)11.03 (8.78 to 13.86)11.85 (9.63 to 14.56)
Common Serotypes-Serotype 9V (n=83,100,78,94)0.43 (0.37 to 0.51)0.43 (0.37 to 0.50)2.55 (2.15 to 3.02)2.75 (2.37 to 3.18)
Common Serotypes-Serotype 14 (n=83,100,78,93)1.59 (1.27 to 2.00)2.00 (1.66 to 2.41)7.68 (6.08 to 9.70)10.24 (8.23 to 12.74)
Common Serotypes-Serotype 18C (n=83,100,78,94)0.25 (0.22 to 0.30)0.40 (0.34 to 0.46)2.57 (2.08 to 3.18)4.08 (3.42 to 4.87)
Common Serotypes-Serotype 19F (n=82,100,78,93)0.81 (0.66 to 1.00)0.60 (0.49 to 0.72)6.34 (5.06 to 7.94)3.97 (3.26 to 4.85)
Common Serotypes-Serotype 23F (n=83,100,78,93)0.29 (0.24 to 0.36)0.38 (0.31 to 0.47)3.36 (2.70 to 4.18)4.79 (3.86 to 5.94)
Additional Serotypes-Serotype 1 (n=83,90,78,91)0.68 (0.56 to 0.82)0.04 (0.03 to 0.04)3.44 (2.79 to 4.23)0.03 (0.03 to 0.04)
Additional Serotypes-Serotype 3 (n=83,98,78,92)0.27 (0.23 to 0.32)0.09 (0.07 to 0.12)1.11 (0.94 to 1.33)0.10 (0.08 to 0.12)
Additional Serotypes-Serotype 5 (n=83,92,78,78)1.01 (0.87 to 1.18)0.40 (0.31 to 0.50)3.92 (3.27 to 4.69)0.56 (0.45 to 0.70)
Additional Serotypes-Serotype 6A (n=82,96,78,92)0.81 (0.68 to 0.96)0.27 (0.22 to 0.33)8.06 (6.60 to 9.85)1.68 (1.27 to 2.21)
Additional Serotypes-Serotype 7F (n=83,91,78,85)0.58 (0.50 to 0.67)0.04 (0.03 to 0.05)2.67 (2.26 to 3.16)0.05 (0.04 to 0.06)
Additional Serotypes-Serotype19A (n=83,100,78,93)0.85 (0.67 to 1.09)0.64 (0.52 to 0.79)5.60 (4.60 to 6.83)2.82 (2.32 to 3.41)
SecondaryPercentage of Participants Achieving Predefined Antibody Levels for Haemophilus Influenzae Type b, Diphtheria Toxoid, Polio, Pertussis, Tetanus, and Hepatitis B in 13vPnC Group Relative to 7vPnC Group After the Infant Series

Percentage of participants achieving predefined antibody threshold levels for Haemophilus Influenzae Type b (Hib) polyribosylribitol phosphate (PRP), Diphtheria Toxoid, Polio (Types 1, 2, and 3), Pertussis (filamentous hemagglutinin \[FHA\], Pertussis Toxoid, and Pertactin), Tetanus, and Hepatitis B with the corresponding 95% CI for each concomitant antigen are presented.

Time frame:
One month after the infant series (7 months of age)
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Predefined Antibody Levels for Haemophilus Influenzae Type b, Diphtheria Toxoid, Polio, Pertussis, Tetanus, and Hepatitis B in 13vPnC Group Relative to 7vPnC Group After the Infant Series
Percentage of participants13vPnC7vPnC
Hib (PRP) 0.15 μg/mL (n=84,87)89.29 (80.63 to 94.98)86.21 (77.15 to 92.66)
Hib (PRP) 1.0 μg/mL (n=84,87)70.24 (59.27 to 79.73)63.22 (52.20 to 73.31)
Diphtheria 0.01 IU/mL (n=38,48)100.00 (90.75 to 100.00)100.00 (92.60 to 100.00)
Diphtheria 0.1 IU/mL (n=38,48)100.00 (90.75 to 100.00)100.00 (92.60 to 100.00)
Tetanus 0.01 IU/mL (n=38,48)100.00 (90.75 to 100.00)100.00 (92.60 to 100.00)
Tetanus 0.1 IU/mL (n=38,48)100.00 (90.75 to 100.00)100.00 (92.60 to 100.00)
Polio Type 1 (antibody threshold ≥1:8) (n=61,64)100.00 (94.13 to 100.00)100.00 (94.40 to 100.00)
Polio Type 2 (antibody threshold ≥1:8) (n=61,64)98.36 (91.20 to 99.96)100.00 (9.40 to 100.00)
Polio Type 3 (antibody threshold ≥1:8) (n=61,63)98.36 (91.20 to 99.96)100.00 (94.31 to 100.00)
Hepatitis b 10 mIU/mL (n=38,48)100.00 (90.75 to 100.00)100.00 (92.60 to 100.00)
Pertussis - FHA 82.00 EU/MI (n=65,68)93.85 (84.99 to 98.30)95.59 (87.64 to 99.08)
Pertussis - Pertussis Toxoid 43.00 EU/mL (n=65,68)89.23 (79.06 to 95.56)95.59 (87.64 to 99.08)
Pertussis - Pertactin 18.00 EU/mL (n=65,68)96.92 (89.32 to 99.63)95.59 (87.64 to 99.08)
Statistical analysis
  • 13vPnC vs 7vPnC · Difference: 3.08 · 95% CI -7.22 to 13.73
  • 13vPnC vs 7vPnC · Difference: 7.02 · 95% CI -7.28 to 21.14
  • 13vPnC vs 7vPnC · Difference: 0.00 · 95% CI -9.38 to 7.73
  • 13vPnC vs 7vPnC · Difference: 0.00 · 95% CI -9.38 to 7.73
  • 13vPnC vs 7vPnC · Difference: 0.00 · 95% CI -5.97 to 5.68
  • 13vPnC vs 7vPnC · Difference: -1.64 · 95% CI -8.80 to 4.24
  • 13vPnC vs 7vPnC · Difference: -1.64 · 95% CI -8.80 to 4.21
  • 13vPnC vs 7vPnC · Difference: 0.00 · 95% CI -9.38 to 7.73
  • 13vPnC vs 7vPnC · Difference: -1.74 · 95% CI -11.00 to 6.99
  • 13vPnC vs 7vPnC · Difference: -6.36 · 95% CI -17.03 to 3.16
  • 13vPnC vs 7vPnC · Difference: 1.33 · 95% CI -6.79 to 9.68
SecondaryGeometric Mean Antibody Concentration of Haemophilus Influenzae Type b in 13vPnC Group Relative to 7vPnC Group After the Infant Series
Time frame:
one month after the infant series (7 months of age)
Reported as:
Geometric mean · μg/mL
Geometric Mean Antibody Concentration of Haemophilus Influenzae Type b in 13vPnC Group Relative to 7vPnC Group After the Infant Series
μg/mL13vPnC7vPnC
Geometric Mean Antibody Concentration of Haemophilus Influenzae Type b in 13vPnC Group Relative to 7vPnC Group After the Infant Series1.99 (1.34 to 2.97)1.64 (1.09 to 2.47)
Statistical analysis
  • 13vPnC vs 7vPnC · Ratio: 1.21 · 95% CI 0.69 to 2.14
SecondaryGeometric Mean Antibody Concentration of Hepatitis B in 13vPnC Group Relative to 7vPnC Group After the Infant Series

GMCs of anti-hepatitis B surface antigen (HBsAg) using a Food and Drug Administration (FDA) approved in vitro diagnostic kit are presented.

Time frame:
one month after the infant series (7 months of age)
Reported as:
Geometric mean · milli International Units (mIU)/mL
Geometric Mean Antibody Concentration of Hepatitis B in 13vPnC Group Relative to 7vPnC Group After the Infant Series
milli International Units (mIU)/mL13vPnC7vPnC
Geometric Mean Antibody Concentration of Hepatitis B in 13vPnC Group Relative to 7vPnC Group After the Infant Series1257.74 (904.77 to 1748.42)1300.01 (976.91 to 1729.99)
Statistical analysis
  • 13vPnC vs 7vPnC · Ratio: 0.97 · 95% CI 0.63 to 1.48
SecondaryGeometric Mean Antibody Concentration Diphtheria Toxoid and Anti-Tetanus Toxoid in 13vPnC Group Relative to 7vPnC Group After the Infant Series
Time frame:
one month after the infant series (7 months of age)
Reported as:
Geometric mean · IU/mL
Geometric Mean Antibody Concentration Diphtheria Toxoid and Anti-Tetanus Toxoid in 13vPnC Group Relative to 7vPnC Group After the Infant Series
IU/mL13vPnC7vPnC
Diphtheria Toxoid0.86 (0.65 to 1.14)1.04 (0.80 to 1.34)
Anti-Tetanus Toxoid0.93 (0.72 to 1.22)0.97 (0.73 to 1.28)
Statistical analysis
  • 13vPnC vs 7vPnC · Ratio: 0.83 · 95% CI 0.57 to 1.21
SecondaryGeometric Mean Antibody Concentration of Polio in 13vPnC Group Relative to 7vPnC Group After the Infant Series
Time frame:
one month after the infant series (7 months of age)
Reported as:
Geometric mean · titer
Geometric Mean Antibody Concentration of Polio in 13vPnC Group Relative to 7vPnC Group After the Infant Series
titer13vPnC7vPnC
Polio Type 1 (n=61,64)483.72 (352.52 to 663.75)479.79 (361.79 to 636.26)
Polio Type 2 (n=61,64)368.26 (250.75 to 540.84)403.45 (249.90 to 551.96)
Polio Type 3 (n=61,63)914.01 (638.80 to 1307.80)812.75 (577.32 to 1144.18)
Statistical analysis
  • 13vPnC vs 7vPnC · Ratio: 1.01 · 95% CI 0.66 to 1.53
  • 13vPnC vs 7vPnC · Ratio: 0.91 · 95% CI 0.56 to 1.49
  • 13vPnC vs 7vPnC · Ratio: 1.12 · 95% CI 0.69 to 1.84
SecondaryGeometric Mean Antibody Concentration of Pertussis Antigens in 13vPnC Group Relative to 7vPnC Group After the Infant Series
Time frame:
one month after the infant series (7 months of age)
Reported as:
Geometric mean · EU/mL
Geometric Mean Antibody Concentration of Pertussis Antigens in 13vPnC Group Relative to 7vPnC Group After the Infant Series
EU/mL13vPnC7vPnC
Pertussis - filamentous hemagglutinin (FHA)207.85 (178.72 to 241.74)225.12 (191.97 to 264.01)
Pertussis - pertussis toxoid (PT)98.68 (82.89 to 117.49)96.58 (86.45 to 107.89)
Pertussis - pertactin141.23 (113.02 to 176.48)135.51 (107.13 to 171.41)
Statistical analysis
  • 13vPnC vs 7vPnC · Ratio: 0.92 · 95% CI 0.74 to 1.15
  • 13vPnC vs 7vPnC · Ratio: 1.02 · 95% CI 0.83 to 1.25
  • 13vPnC vs 7vPnC · Ratio: 1.04 · 95% CI 0.76 to 1.44
SecondaryPercentage of Participants Achieving Antibody Titer (OPA) ≥1:8 in 13vPnC Group Relative to 7vPnC Group After the 3-Dose Infant Series

Percentage of participants achieving functional antibody titer ≥1:8 as measured by opsonophagocytic activity assay (OPA) along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

Time frame:
one month after the infant series (7 months of age)
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Antibody Titer (OPA) ≥1:8 in 13vPnC Group Relative to 7vPnC Group After the 3-Dose Infant Series
Percentage of participants13vPnC7vPnC
Common Serotypes - Serotype 4 (n=30,33)96.67 (82.78 to 99.92)100.00 (89.42 to 100.00)
Common Serotypes - Serotype 6B (n=27,30)92.59 (75.71 to 99.09)93.33 (77.93 to 99.18)
Common Serotypes - Serotype 9V (n=27,27)100.00 (87.23 to 100.00)100.00 (87.23 to 100.00)
Common Serotypes - Serotype 14 (n=27,30)100.00 (87.23 to 100.00)100.00 (88.43 to 100.00)
Common Serotypes - Serotype 18C (n=27,30)100.00 (87.23 to 100.00)96.67 (82.78 to 99.92)
Common Serotypes - Serotype 19F (n=25,25)84.00 (63.92 to 95.46)80.00 (59.30 to 93.17)
Common Serotypes - Serotype 23F (n=27,26)92.59 (75.71 to 99.09)100.00 (86.77 to 100.00)
Additional Serotypes - Serotype 1 (n=30,32)83.33 (65.28 to 94.36)6.25 (0.77 to 20.81)
Additional Serotypes - Serotype 3 (n=25,29)80.00 (59.30 to 93.17)3.45 (0.09 to 17.76)
Additional Serotypes - Serotype 5 (n=30,33)100.00 (88.43 to 100.00)6.06 (0.74 to 20.23)
Additional Serotypes - Serotype 6A (n=25,29)96.00 (79.65 to 99.90)48.28 (29.45 to 67.47)
Additional Serotypes - Serotype 7F (n=22,24)100.00 (84.56 to 100.00)20.83 (7.13 to 42.15)
Additional Serotypes - Serotype 19A (n=22,24)77.27 (54.63 to 92.18)12.50 (2.66 to 32.36)
SecondaryPercentage of Participants Achieving Antibody Titer (OPA) ≥1:8 in 13vPnC Group Relative to 7vPnC Group After the Toddler Dose

Percentage of participants achieving functional antibody titer ≥1:8 as measured by opsonophagocytic activity assay (OPA) along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) were assessed. Results are reported for the serotypes with a determinate antibody titer.

Time frame:
One month after the toddler dose (13 to 16 months of age)
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Antibody Titer (OPA) ≥1:8 in 13vPnC Group Relative to 7vPnC Group After the Toddler Dose
Percentage of participants13vPnC7vPnC
Additional Serotypes - Serotype 6A (n=73,70)100.00 (95.1 to 100.00)90.0 (80.5 to 95.9)
Additional Serotypes - Serotype 19A (n=71,72)100.00 (94.9 to 100.00)51.4 (39.3 to 63.3)
SecondaryGeometric Mean Antibody Titer (OPA) in 13vPnC Group Relative to 7vPnC Group After the Toddler Dose

Antibody functionality/geometric mean titer (GMT) as measured by opsonophagocytic activity assay (OPA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) were assessed. Results are reported for the serotypes with a determinate antibody titer.

Time frame:
One month after the Toddler Dose (13 to 16 months of age)
Reported as:
Geometric mean · titer
Geometric Mean Antibody Titer (OPA) in 13vPnC Group Relative to 7vPnC Group After the Toddler Dose
titer13vPnC7vPnC
Additional Serotypes - Serotype 6A (n=73,70)2147.58 (1630.73 to 2828.23)599.90 (375.83 to 957.54)
Additional Serotypes - Serotype 19A (n=71,72)802.24 (633.92 to 1015.24)36.62 (21.09 to 63.59)

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
13vPnC Infant Series—9/120 (7.5%)104/120 (86.7%)
7vPnC Infant Series—9/126 (7.1%)110/126 (87.3%)
13vPnC Toddler Dose—1/86 (1.2%)33/86 (38.4%)
7vPnC Toddler Dose—0/103 (0%)51/103 (49.5%)
13vPnC 6-Month Follow-up—4/86 (4.7%)20/86 (23.3%)
7vPnC 6-Month Follow-up—1/103 (1%)33/103 (32%)
Most frequent serious events
Showing 10 of 32
Most frequent serious events
Event13vPnC Infant Series7vPnC Infant Series13vPnC Toddler Dose7vPnC Toddler Dose13vPnC 6-Month Follow-up7vPnC 6-Month Follow-up
BronchiolitisInfections and infestations3/1203/1260/860/1031/860/103
Status asthmaticusRespiratory, thoracic and mediastinal disorders0/1200/1261/860/1032/860/103
DehydrationMetabolism and nutrition disorders2/1202/1260/860/1030/860/103
Asthma exacerbationRespiratory, thoracic and mediastinal disorders0/1200/1260/860/1031/861/103
Complex febrile seizureNervous system disorders0/1200/1260/860/1031/860/103
Fever of unknown originInfections and infestations1/1200/1260/860/1031/860/103
RSV positive bronchiolitisRespiratory, thoracic and mediastinal disorders0/1201/1260/860/1031/860/103
SeizureNervous system disorders0/1200/1260/860/1031/860/103
Viral URIInfections and infestations0/1200/1260/860/1031/860/103
Viral conjunctivitisInfections and infestations0/1200/1261/860/1030/860/103
Most frequent other events
Showing 10 of 219
Most frequent other events
Event13vPnC Infant Series7vPnC Infant Series13vPnC Toddler Dose7vPnC Toddler Dose13vPnC 6-Month Follow-up7vPnC 6-Month Follow-up
IrritabilityGeneral disorders79/11888/12433/8548/101——
IrritabilityGeneral disorders69/11067/118————
Increased sleepGeneral disorders67/11967/12424/8644/101——
IrritabilityGeneral disorders55/10763/117————
Upper respiratory tract infectionInfections and infestations57/12065/1268/8610/1035/8612/103
Increased sleepGeneral disorders47/11155/118————
Tenderness (Any)Skin and subcutaneous tissue disorders41/11954/12419/8530/101——
Increased sleepGeneral disorders37/10748/117————
Tenderness (Any)Skin and subcutaneous tissue disorders31/11043/118————
Otitis mediaInfections and infestations40/12037/1261/8610/1039/8614/103

Baseline characteristics

Age Continuous
Age Continuous(weeks)13vPnC7vPnCTotal
Mean9.2 ± 1.49.1 ± 1.29.2 ± 1.3
Sex: Female, Male
Sex: Female, Male(Participants)13vPnC7vPnCTotal
Female5859117
Male6367130
08

Study locations

1 site
  • New York, New York 10045, United States
09

References and documents

Publications

  • Bryant KA, Block SL, Baker SA, Gruber WC, Scott DA; PCV13 Infant Study Group. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine. Pediatrics. 2010 May;125(5):866-75. doi: 10.1542/peds.2009-1405. PubMed 20435707 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2004 and a completion of May 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2005
First posted
Sep 20, 2005
Start
Sep 2004
CompletionActual
May 2007
Results first posted
Aug 15, 2012
Last update
Aug 15, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00205803
Responsible party
Sponsor
First posted
Sep 20, 2005
Start date
Sep 2004
Completion
May 2007
Results posted
Aug 15, 2012
Last update
Aug 15, 2012

Study contacts

Medical Monitor
study director · Wyeth is now a wholly owned subsidiary of Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 13-valent pneumococcal vaccine

Start the discussion